Difference between revisions of "Fluoxetine-vortioxetine"

From Psychiatrienet
Jump to: navigation, search
m
Line 7: Line 7:
 
| start =  
 
| start =  
 
* A wash-out period is not necessary, but care is needed.
 
* A wash-out period is not necessary, but care is needed.
* '''Day 1:''' start administration of vortioxetine the next day in a dosage of 10 mg/day.
+
* '''Day 1:''' start administration of vortioxetine in a dosage of 10 mg/day.
 
| info =
 
| info =
 
* Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine.  
 
* Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine.  
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
}}
 
}}

Revision as of 15:21, 4 March 2015

Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine

Switch medication from fluoxetine to vortioxetine.[1] [2]

Nietinrijdenbord.png Stop fluoxetine
  • Before day 1: gradually reduce dosage of escitalopram to a maximum of 10 mg/day, when this dosage is > 10 mg/day.
  • Day 1: when a dosage of 10 mg/day is reached, stop administration
Eenrichtingbord.png Start vortioxetine
  • A wash-out period is not necessary, but care is needed.
  • Day 1: start administration of vortioxetine in a dosage of 10 mg/day.
Infobord.png More information
  • Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine.
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.